Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp34 | Bone biomechanics and quality | ECTS2014

The surface and the volume trace element compound of the of biological bone apatite

Gusak Eugeniya , Vladimir Kuznetsov , Alexandr Kochnko , Elena Gordienko , Sergii Danilchenko , Maksym Pogorielov

The bioapatite crystals have a multilayer hydrate shell, which contains impurity ions such as magnesium, sodium, potassium and it is not clear the qualitative and quantitative characteristics of noapatite entourage. The major component noapatite environment in bone is water and we studied the surface of nanocrystals from trabecular bone in healthy rats and during the water deficiency.In experiment we use adult laboratory rats (8 months age), remove the c...

ba0003pp77 | Bone development/growth and fracture repair | ECTS2014

Elevated blood serotonin decreases bone volume via a mechanism involving insulin and calcitriol

Erjavec Igor , Bordukalo-Niksic Tatjana , Brkljacic Jelena , Grcevic Danka , Pauk Martina , Grgurevic Lovorka , Mokrovic Gordana , Kesic Maja , Durdevic Dragan , Rogic Dunja , Thompson David D , Paralkar Vishwas M , Cicin-Sain Lipa , Vukicevic Slobodan

To further characterize the role of serotonin (5HT) in bone metabolism, Wistar-Zagreb rat model consisting of the high-5HT and low-5HT subline with different platelet 5HT content and transporter (5HTT) activity has been used.Primary osteoclasts from the high-5HT subline had an increased expression of 5HTT, 5HT–2A receptor, Trap and cathepsin K, while osteoblasts showed no difference in the expression of 5HT elements or osteoblastic markers. However,...

ba0003pp90 | Bone development/growth and fracture repair | ECTS2014

A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemia

Carpenter Thomas , Imel Erik , Ruppe Mary , Weber Thomas , Klausner Mark , Wooddell Margaret , Kawakami Tetsuyoshi , Ito Takahiro , Zhang Xiaoping , Humphrey Jeffrey , Insogna Karl , Peacock Munro

Purpose: In X-linked hypophosphatemia (XLH), elevated serum FGF23 causes low serum phosphorus (Pi) and inappropriately normal 1,25-dihydroxyvitamin D (1,25(OH)2D) levels. We report safety, tolerability and biochemistry markers following single ascending dose administration of KRN23 in adults with XLH.Methods: 38 XLH subjects with baseline FGF23≥30 pg/ml were randomized to receive single doses of KRN23 (K) or placebo (P) either (0.003&#15...

ba0003pp91 | Bone development/growth and fracture repair | ECTS2014

Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) after ascending single-dose administration in patients with X-linked hypophosphatemia

Zhang Xiaoping , Carpenter Thomas , Imel Erik , Ruppe Mary , Weber Thomas , Klausner Mark , Kawakami Tetsuyoshi , Ito Takahiro , Humphrey Jeffrey , Insogna Karl , Peacock Munro

Purpose: In X-linked hypophosphatemia (XLH), elevated serum FGF23 causes low serum phosphorus (Pi) and inappropriately normal 125-dihydroxyvitamin D (125(OH)2D) levels. We report PK and PD of KRN23 following single ascending dose administration in adults with XLH.Methods: 38 XLH patients with baseline FGF23≥30 pg/ml were randomized to receive a single dose of KRN23 (K) or placebo (P) either i.v. (0.003–0.3 mg/kg) or s.c. (0.1–1...

ba0003pp154 | Cell biology: osteoclasts and bone resorption | ECTS2014

Disruption of PLEKHM1 and TRAFD1 (FLN29) interaction impairs osteoclast resorptive activity

Witwicka Hanna , Jia Hong , Kutikov Artem , Hwang Sung-Yong , Odgren Paul

Mutations in PLEKHM1 cause bone disease in humans and animals. Truncations causedeficient bone resorption by osteoclasts leading to osteopetrosis. A gain-of-function point mutation causes increased resorption leading to osteopenia. We and others have shown that PLEKHM1, a multi-modular protein, interacts with the small GTPase rab7 and is involved in vesicle trafficking, secretion, and membrane biogenesis. To investigate other interactions of PLEKHM1 we performed tandem affinit...

ba0003pp161 | Cell biology: osteoclasts and bone resorption | ECTS2014

Ultrastructural imaging of the osteoclast secretory machinery in 3 dimensions

Helfrich Miep , Wilkinson Debbie , Mackenzie Kevin , Greenhorn John , Coxon Fraser

Osteoclasts secrete acid and cathepsin K to dissolve the mineral and digest the organic matrix of bone, cartilage and dentine. The secretions are by necessity destructive and potentially harmful to the cell itself and are therefore trafficked through the cell in membrane bound vesicles. Secretion takes place over a specialised membrane compartment, the ruffled border, which is only present in resorbing osteoclasts. The ruffled border membrane and the vesicles in its vicinity h...

ba0003pp193 | Genetics | ECTS2014

MK-7 enhances expression of genes related to bone, enamel and dentin, and reduces the expression of genes related to apoptosis in developing murine molars

Landin Maria A. , Shabestari Yashar , Sehic Amer , Osmundsen Harald

Introduction: The fat-soluble and vitamin K2 homologe Menaquinone-7 (MK-7) is needed for post-translational modification of proteins essential in blood coagulation, and in metabolic pathways in various tissues like bone. Recent studies found an association between long-term anticoagulant treatment (OAC) and reduced bone quality due to reduction of active osteocalcin. OAC is often linked to an undesired soft-tissue calcification in both children and adults and may lead to incre...

ba0003pp294 | Osteoporosis: treatment | ECTS2014

Targeting the sealing zone, a novel strategy to prevent bone degradation while maintaining bone formation: in vivo proof of concept in three models of pathological bone loss

Vives Virginie , Cress Gaelle , Richard Chrtistian , Blangy Anne

Molecules secreted by the osteoclast or ‘clastokynes’ are essential to stimulate bone formation by osteoblasts. Treatments with bisphosphates and Denosumab target osteoclast survival and differentiation. This suppresses bone turnover and is suspected to increase the risk of atypical fractures in the long term. A solution to overcome this is to develop strategies that target selectively the activity of osteoclasts without affecting their survival or differentiation. S...

ba0003pp316 | Osteoporosis: treatment | ECTS2014

Odanacatib treatment improves lumbar vertebral bone mineral density and strength in orchiectomized rabbits

Duong Le T , Chen Charles , Pennypacker Brenda L

The selective cathepsin K inhibitor odanacatib (ODN) is currently in development for the treatment of postmenopausal osteoporosis. Our goal was to evaluate the effects of ODN vs alendronate (ALN) on bone mass and strength of lumbar vertebrae (LV) in orchiectomized (ORX) rabbits, a model of male osteoporosis. Adult male rabbits (11 months old) were subjected to sham- (n=20) or ORX-surgery (n=24/group) for 7.5 months before dosing initiated. ORX animals were ra...

ba0003pp373 | Other diseases of bone and mineral metabolism | ECTS2014

Involvement of Gla rich protein with pathological calcification during osteoarthritis. Insights into its γ-carboxylation status

Rafael Marta , Cavaco Sofia , Viegas Carla , Santos Sofia , Ramos Acacio , Luis Ines , Costa Ruben , Willems Brecht , Herfs Marjolein , Theuwissen Elke , Vermeer Cees , Simes Dina

Gla-rich protein (GRP) is a vitamin K-dependent protein, characterized by a high density of γ-carboxylated Glu residues and high calcium binding affinity. It was shown to accumulate in mouse and sturgeon cartilage and in sites of skin and vascular calcification in humans. Four alternatively spliced transcripts of the GRP gene (GRP–F1, F2, F3 and F4) were described in mouse chondrocytes and zebrafish. Osteoarthritis (OA) is a common degenerative joint disease...